# EDGAR Filing Document

**Accession Number:** 0001000683
**File Stem:** 0001213900-23-001390
**Filing Date:** 2023-1
**Character Count:** 18387
**Document Hash:** e951290958c8d64298d8c486281d274e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-001390.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001213900-23-001390

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20221230

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BLONDER TONGUE LABORATORIES INC
- **CENTRAL INDEX KEY:** 0001000683
- **STANDARD INDUSTRIAL CLASSIFICATION:** RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT [3663]
- **IRS NUMBER:** 521611421
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14120
- **FILM NUMBER:** 23515383

**BUSINESS ADDRESS:**
- **STREET 1:** ONE JAKE BROWN RD
- **STREET 2:** PO BOX 1000
- **CITY:** OLD BRIDGE
- **STATE:** NJ
- **ZIP:** 08857
- **BUSINESS PHONE:** 9086794000

**MAIL ADDRESS:**
- **STREET 1:** ONE JAKE BROWN ROAD
- **CITY:** OLD BRIDGE
- **STATE:** NJ
- **ZIP:** 08857

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): <u>December 30, 2022</u>**

**<u>Blonder Tongue Laboratories, Inc.</u>**

**(Exact Name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-14120** | **52-1611421** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission File Number)** | **(I.R.S. Employer<br> Identification No.)** |

---

**<u>One Jake Brown Road, Old Bridge, New Jersey 08857</u>**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: <u>(732) 679-4000</u>**

**<u>Not Applicable</u>**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| **NONE** | **NONE** | **NONE** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As previously reported on a Current Report on Form 8-K, filed on May 23, 2022, on May 18, 2022, the Board of Directors (the "Board") of Blonder Tongue Laboratories, Inc. (the "Company"), acting on the recommendation of the compensation committee of the Board (the "Compensation Committee"), and the Company's chief executive officer, Edward R. Grauch (the "Executive"), agreed to make certain adjustments to the Executive's compensation, to defer all of his cash compensation for a period of 180 days beginning May 23, 2022. As of each date on which compensation that would otherwise have been paid to Mr. Grauch, the Company will accrue a number of shares of its common stock calculated by dividing (i) the dollar amount of the deferred compensation for such date by (ii) the fair market value of one share of the Company's common stock. The deferred compensation will be paid to Mr. Grauch on or before March 15, 2023.

On December 30, 2022, the Board, acting on the recommendation of the Compensation Committee, agreed to make certain adjustments to the compensation of the Executive, whereby pursuant to a deferred compensation agreement, entered into by and between the Company and the Executive on December 30, 2022 (the "December 2022 Deferred Compensation Agreement"), the Executive agreed to defer all of his cash compensation from the Company (the "Accrued Compensation") during the period beginning on January 1, 2023 and ending on June 3, 2023 (the "Suspension Period").

Pursuant to the December 2022 Deferred Compensation Agreement, on or before June 30, 2023, the Company shall deliver to the Executive the full amount of the Accrued Compensation, subject to compliance with tax withholding obligations as described in the December 2022 Deferred Compensation Agreement. The form of payment of the Accrued Compensation shall be via: (1) payment of cash; (2) the issuance of that number of shares of the Company's common stock derived by dividing (a) the amount of Accrued Compensation, by (b) the Fair Market Value of one share of the common stock as of such date (the "Compensation Shares"); or (3) a combination of cash and Compensation Shares. The form of payment of the Accrued Compensation shall be at the sole discretion of the Board.

The Compensation Shares issued, if any, will be issued under and pursuant to the Company's Second Amended and Restated Executive Stock Purchase Plan, approved by the Board on September 10, 2020, as amended, and will be validly issued, fully paid and non-assessable when delivered.

In addition, in the event of a Change in Control, as defined in the December 2022 Deferred Compensation Agreement, prior to the delivery of the cash and/or Compensation Shares, all further suspensions of payment of the Executive's compensation shall cease, and the Accrued Compensation as of the date of such Change in Control shall be immediately payable to the Executive in cash, subject to all applicable tax withholding obligations.

Item 5.02 of this Current Report on Form 8-K contains only a brief description of the material terms of and does not purport to be a complete description of the rights and obligations of the parties to the December 2022 Deferred Compensation Agreement, and such description is qualified in its entirety by reference to the full text of the December 2022 Deferred Compensation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1\* | [Deferred Compensation Agreement, by and between Blonder Tongue Laboratories, Inc. and Edward R. Grauch, dated December 30, 2022](ea171337ex10-1_blonder.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

\* Filed herewith.

<u>SIGNATURE</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BLONDER TONGUE LABORATORIES, INC.** | **BLONDER TONGUE LABORATORIES, INC.** |
| Dated: January 6, 2023 | By: | */s/ Eric Skolnik* |
|  |  | Eric Skolnik |
|  |  | Senior Vice President and Chief Financial Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**BLONDER TONGUE** 

**EXECUTIVE DEFERRED COMPENSATION AGREEMENT**

THIS DEFERRED COMPENSATION AGREEMENT ("**Agreement**") is made as of this 30th day of December, 2022 (the "**Effective Date**"), by and between BLONDER TONGUE LABORATORIES, INC., a Delaware corporation (the "**Company**"), and Edward R. Grauch (the "**Executive**").

<u>WITNESSETH</u>:

WHEREAS, the Company and the Executive desire to defer payment of certain compensation otherwise payable by the Company to the Executive.

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereinafter set forth, and intending to be legally bound hereby, the parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Payment of one hundred percent (100%) of the cash compensation from the Company earned by the Executive as its employee during the period beginning on January 1, 2023 and ending on June 3, 2023 (the "**Suspension Period**"), shall be suspended and not paid to Executive or any other person except as set forth in this Agreement. The cash compensation from the Company earned by the Executive as its employee during the Suspension Period is referred to herein as the "**Accrued Compensation**."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. On or before June 30, 2023, the Company shall deliver to the Executive, or to the personal representative of the Executive in the event of his earlier death (in either case, the "**Distributee**"), the full amount of the Accrued Compensation, subject to compliance with the tax withholding obligations described in paragraph 4 below, via: (1) payment of cash; (2) the issuance of that number of shares of the Company's common stock derived by dividing (a) the amount of Accrued Compensation, by (b) the Fair Market Value of one share of the common stock as of such date (the "**Compensation Shares**"); or (3) a combination of cash and Compensation Shares. The form of payment of the Accrued Compensation shall be at the sole discretion of the Company's Board of Directors (the "**Board**"). For purposes of this Agreement, the "**Fair Market Value**" of the Company's common stock shall mean (i) if the common stock is traded on the over-the-counter market, the arithmetic mean of the bid and the asked prices for the common stock at the close of trading on that date, or if that day is not a trading day on the trading day immediately preceding such day; (ii) if the common stock is listed on a national securities exchange, the official closing price on the consolidated tape on that date, or if that day in not a trading day on the trading day immediately preceding such day; and (iii) if the common stock is neither traded on the over-the-counter market nor listed on a national securities exchange, such value as the Compensation Committee of the Board, in good faith, shall determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Compensation Shares issued, if any, (i) will be issued under and pursuant to the Company's Second Amended and Restated Executive Stock Purchase Plan, approved by the Board on September 10, 2020, as amended (the "**Plan**") and, as such, this Agreement shall be deemed to serve as a Notice of Election under and as defined in the Plan, on the terms described herein and otherwise in accordance with the terms and provisions of the Plan (except that, in the case of any provisions in this Agreement that are inconsistent with the provisions of the Plan, this Agreement will control), (ii) will be issued pursuant to an exemption from registration under the Securities Act of 1933, as amended (the "**Securities Act**"), (ii) will be "restricted securities," as such term is defined in Rule 144 under the Securities Act, (iii) may be resold or otherwise transferred only pursuant to an effective registration statement under the Securities Act or applicable exemption from registration and (iv) when delivered, will be validly issued, fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Company shall have the authority and the right to deduct or withhold, or require the Distributee to remit to the Company, an amount sufficient to satisfy Federal, state, local and foreign taxes required by law to be withheld with respect to the delivery of the cash and / or the Compensation Shares pursuant to paragraph 2 above. The Distributee may elect to have the Company withhold from the total number of Compensation Shares that would otherwise have been delivered to the Distributee that number of shares having a Fair Market Value equal to the minimum statutory amount necessary to satisfy the Company's applicable federal, state, local and foreign tax withholding obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Notwithstanding any provision of this Agreement, in the event of a Change in Control prior to the delivery of the cash and / or the Compensation Shares pursuant to paragraph 2 above, all further suspensions of payment of the Executive's compensation shall cease, and the Accrued Compensation as of the date of such Change and Control shall be immediately payable to the Executive, or to the personal representative of the Executive in the event of his earlier death, in cash, subject to all applicable federal, state, local and foreign tax withholding obligations. For purposes of this Agreement, "**Change in Control**" shall mean the consummation of any of the following, provided that such transaction or occurrence results in a change in ownership or effective control of the Company, or in the change in ownership of a substantial portion of the assets of the Company, in either case within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended: (a) any consolidation or merger of the Company with or into any other entity, or any corporate reorganization; (b) any transaction (or series of related transactions involving a person or entity or group of affiliated persons or entities) in which in excess of a majority of the voting power of the Company is transferred, including any consolidation or merger; or (c) any sale, lease or other disposition of all or substantially all of the assets of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Neither the Executive nor his estate shall have any power or right to transfer, assign, anticipate, mortgage, commute or otherwise encumber any of the benefits payable hereunder, nor shall such benefits be subject to seizure for the payment of any debts or judgments of either of them or to be transferable by operation of law in the event of bankruptcy, insolvency or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Neither the Executive nor his estate shall have any right, title, or interest in or to any fund, investments, insurance policies or annuity contracts which the Company may make or acquire to aid it in meeting its obligations hereunder. The rights of such persons to the payment or provision of benefits pursuant to this Agreement are those of a general unsecured creditor or the Company. It is the intention of the Company that the deferred compensation to which any person may be entitled under this Agreement shall be unfunded for Federal income tax purposes and for purposes of the Employee Retirement Income Security Act of 1974, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. This Agreement shall be construed and enforced according to the laws of the State of Delaware and shall inure to the successors and assigns of the Company, whether by merger, consolidation or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. The parties agree that with respect to the subject matter herein contained, it is the entire agreement by the parties, superseding any prior oral or written communications, representations, undertakings or agreements and shall not be amended, modified or changed, except in a writing duly executed by the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. By signing below, Executive acknowledges and agrees that he has not received legal or tax advice from the Company with respect to this Agreement; have had an opportunity to consult with his own tax counsel as to the U.S. federal, state, local and foreign tax consequences of this Agreement; have had an opportunity to consult with his own independent legal counsel regarding his rights and obligations under this Agreement; have carefully read this Agreement in its entirety; fully understand and agree to its terms and provisions; and intend and agree that it be final and legally binding on Executive and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original of the same instrument, but all of which together shall constitute but one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.

---

| | |
|:---|:---|
| BLONDER TONGUE LABORATORIES, INC. | BLONDER TONGUE LABORATORIES, INC. |
| By: |  |
|  | Eric Skolnik, Senior Vice President and <br> Chief Financial Officer |
| EXECUTIVE: | EXECUTIVE: |
|  | Edward R. Grauch |

---